Advertisement
CANF vs LONA
Which Stock Would AI Choose? Can-Fite BioPharma (CANF) vs. LeonaBio (LONA) Stock Comparison
Key Takeaways
- Both CANF and LONA are pre-revenue, clinical-stage biotechnology companies, making them high-risk, catalyst-driven equities rather than fundamentals-based holdings.
- Can-Fite BioPharma (CANF) recently raised about $4.0 million through a repriced warrant exercise, which pressured shares while funding its oncology and liver-disease pipeline.
- LeonaBio (LONA) has undergone a sharp repricing in recent weeks after a strong start to 2026, though it retains a cash position intended to fund operations into 2028.
- The two companies pursue very different disease areas: CANF targets cancer, liver, and inflammatory conditions, while LONA focuses on metastatic breast cancer and ALS (amyotrophic lateral sclerosis).
- Relative performance has diverged sharply, with CANF trading near its 52-week lows and LONA showing elevated volatility following its January 2026 name and ticker change from Athira Pharma.
- Market positioning, balance-sheet strength, and near-term catalysts are the key differentiators an AI model would weigh when ranking these two names.
Introduction
Comparing two clinical-stage biotechs can be instructive for traders who specialize in high-volatility, event-driven equities. CANF (Can-Fite BioPharma Ltd.) and LONA (LeonaBio, Inc.) both generate minimal or no product revenue, meaning their stock prices are driven primarily by clinical data, financing decisions, and investor sentiment rather than earnings. This stock comparison examines their recent performance, market positioning, and risk profiles to help both momentum traders and longer-horizon biotech investors understand where the two names diverge and where they overlap in the current market environment.
CANF Overview and Recent Performance
Can-Fite BioPharma is an Israel-based, clinical-stage company developing orally bioavailable small-molecule drugs for cancer, liver, and inflammatory diseases. Its lead candidates include Piclidenoson (in late-stage development for psoriasis) and Namodenoson (in Phase III testing for hepatocellular carcinoma, or HCC, the most common form of primary liver cancer, as well as earlier-stage studies in pancreatic cancer).
In recent weeks, CANF has been shaped by both clinical and financing news. The company reported longer-than-anticipated blinded overall survival in its ongoing Phase III Namodenoson liver-cancer study and said it is evaluating an earlier interim analysis timeline. Around the same time, it announced a warrant exercise agreement generating roughly $4.0 million in gross proceeds at a reduced exercise price, a move that diluted existing shareholders and contributed to a notable single-session decline. As a micro-cap ADS (American Depositary Share) issuer with a market capitalization in the single-digit millions, the stock has traded well below its 52-week high, reflecting both pipeline optimism and persistent dilution and funding concerns.
LONA Overview and Recent Performance
LeonaBio is a Seattle-area, clinical-stage biopharmaceutical company that changed its name from Athira Pharma in January 2026 and adopted the ticker LONA. Its lead asset, lasofoxifene, is a SERM (selective estrogen receptor modulator) being studied in the Phase III ELAINE-3 trial for treatment-resistant metastatic breast cancer, while ATH-1105 targets ALS. The company secured a $90 million private placement in late 2025, with warrants that could provide up to roughly $146 million more if fully exercised, supporting operations into 2028.
LONA rallied sharply in early 2026, reaching a 52-week high in the spring, but has since experienced a pronounced sell-off that erased much of those gains. Recent market activity has been characterized by high volatility and elevated trading volume relative to the company's historical average. With no product revenue and a market capitalization that has fluctuated significantly, the stock remains highly sensitive to clinical milestones, financing execution, and broader risk appetite in the small-cap biotech sector.
Trending AI Robots
For traders seeking a more systematic approach to names like CANF and LONA, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, yet only the most suitable performers for current market conditions earn a place in this curated section. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker universes, with varying historical win rates and trade frequencies. Rather than relying on a single approach, the selection highlights bots whose configurations align with prevailing market dynamics. Traders can explore the Trending AI Robots page to identify automated strategies that match their own risk tolerance and trading horizon.
Head-to-Head Comparison
The two companies diverge most clearly in therapeutic focus and financial runway. CANF operates with a leaner capital structure and has leaned on incremental warrant exercises to fund development, creating recurring dilution pressure. LONA carries a larger cash balance and a stated runway into 2028, but its recent repricing suggests the market is reassessing either its pipeline timeline or its capital-efficiency outlook.
On momentum, both stocks have trended lower over recent weeks, but their paths differ. LONA's decline followed a much stronger earlier rally, making its recent volatility more pronounced, while CANF has drifted downward more persistently from its 52-week high. Sector exposure is similar at a high level—both are small-cap biotechnology—but their risk profiles differ: CANF's near-term story hinges on a Phase III liver-cancer readout and continued financing, whereas LONA's hinges on a Phase III breast-cancer program and a neurodegeneration pipeline still in earlier development.
Investor sentiment also contrasts. LONA has received sell-side coverage initiation with a constructive recommendation and holds a consensus price target well above its recent price, while CANF's analyst coverage remains limited and its targets have been adjusted amid dilution and a reverse-split history. Neither stock is suitable for capital-preservation mandates; both require tolerance for binary clinical outcomes and financing risk.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, financial runway, and near-term catalysts, Tickeron's AI would likely view this comparison as narrowly balanced, with the relative edge depending on the weighting of stability versus momentum. LONA currently appears to offer stronger balance-sheet support and a clearer financing runway, which are favorable from a stability standpoint, but its recent sharp decline signals weak short-term trend consistency. CANF offers a nearer-term Phase III catalyst but carries greater dilution risk and lower capitalization. In probabilistic terms, an AI model would likely assign neither stock a decisive advantage, favoring LONA slightly on financial stability while flagging both names for elevated volatility and catalyst dependency.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Hold and LONA is a StrongBuy.
CANF | LONA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 91 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 87 | 65 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LONA's Valuation (11) in the null industry is in the same range as CANF (15) in the Biotechnology industry. This means that LONA’s stock grew similarly to CANF’s over the last 12 months.
LONA's Profit vs Risk Rating (100) in the null industry is in the same range as CANF (100) in the Biotechnology industry. This means that LONA’s stock grew similarly to CANF’s over the last 12 months.
LONA's SMR Rating (100) in the null industry is in the same range as CANF (100) in the Biotechnology industry. This means that LONA’s stock grew similarly to CANF’s over the last 12 months.
LONA's Price Growth Rating (65) in the null industry is in the same range as CANF (87) in the Biotechnology industry. This means that LONA’s stock grew similarly to CANF’s over the last 12 months.
LONA's P/E Growth Rating (100) in the null industry is in the same range as CANF (100) in the Biotechnology industry. This means that LONA’s stock grew similarly to CANF’s over the last 12 months.
| CANF | LONA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 89% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 84% |
| Advances ODDS (%) | 10 days ago 78% | 4 days ago 83% |
| Declines ODDS (%) | 2 days ago 86% | 13 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CANF’s FA Score shows that 1 FA rating(s) are green while LONA’s FA Score has 1 green FA rating(s).
- CANF’s FA Score: 1 green, 4 red.
- LONA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CANF’s TA Score shows that 5 TA indicator(s) are bullish while LONA’s TA Score has 5 bullish TA indicator(s).
- CANF’s TA Score: 5 bullish, 4 bearish.
- LONA’s TA Score: 5 bullish, 5 bearish.
Price Growth
CANF (@Biotechnology) experienced а -12.92% price change this week, while LONA (@Biotechnology) price change was +19.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.51%. For the same industry, the average monthly price growth was -13.43%, and the average quarterly price growth was -4.26%.
Reported Earning Dates
LONA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-2.51% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CANF and
Correlation & Price change
A.I.dvisor indicates that over the last year, CANF has been closely correlated with GNPX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if CANF jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To CANF | 1D Price Change % | ||
|---|---|---|---|---|
| CANF | 100% | -5.00% | ||
| GNPX - CANF | 93% Closely correlated | -1.09% | ||
| ICU - CANF | 91% Closely correlated | +3.44% | ||
| MLEC - CANF | 89% Closely correlated | -48.84% | ||
| LONA - CANF | 78% Closely correlated | N/A | ||
| LNAI - CANF | 72% Closely correlated | +9.82% | ||
More | ||||
LONA and
Correlation & Price change
A.I.dvisor indicates that over the last year, LONA has been closely correlated with CANF. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if LONA jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To LONA | 1D Price Change % | ||
|---|---|---|---|---|
| LONA | 100% | N/A | ||
| CANF - LONA | 77% Closely correlated | -5.00% | ||
| ICU - LONA | 76% Closely correlated | +3.44% | ||
| GNPX - LONA | 62% Loosely correlated | -1.09% | ||
| MLEC - LONA | 58% Loosely correlated | -48.84% | ||
| CNTN - LONA | 40% Loosely correlated | +1.44% | ||
More | ||||